The metabolic syndrome, hyperlipidemia, and insulin resistance.
The metabolic syndrome, hyperlipidemia, and insulin resistance.
复制标题
DOI：
10.1016/s1098-3597(05)80069-9
复制
发表时间：
2005-01-01
期刊：
影响因子：
--
通讯作者：
Fonseca, Vivian A
中科院分区：
文献类型：
--
作者：
Fonseca, Vivian A
代谢综合征是一组与肥胖相关的心血管危险因素。根据国家胆固醇教育计划（NCEP）成人高血胆固醇检测、评估和治疗专家小组第三次报告（成人治疗小组III），代谢综合征的定义组成部分是腰围升高、甘油三酯升高、高密度脂蛋白胆固醇降低、血压升高和空腹血糖升高。代谢综合征的病理生理基础是复杂的，反映了几个相互关联的糖和脂质稳态紊乱。代谢综合征在美国和发达国家很普遍，患有这种疾病的患者有患2型糖尿病和心血管疾病的风险，这强调了及时识别和管理患者的必要性。控制代谢综合征的一线方法是控制体重和锻炼。广泛的药理学干预（例如，他汀类药物、降压药、胰岛素增敏剂和噻唑烷二酮类药物）已被证明可有效控制代谢综合征的单个组分。肥胖是代谢综合征的必要组成部分，在美国已达到流行病的程度。虽然生活方式管理或药物可以控制潜在的危险因素和代谢综合征的大部分组成部分，但长期减肥很难实现。几种有前途的药物干预，可能有一个重要的作用，通过治疗脂肪组织介导的代谢紊乱的代谢综合征的管理是在早期的发展阶段。
The metabolic syndrome is a cluster of cardiovascular risk factors associated with obesity. The defining components of the metabolic syndrome, according to the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), are elevated waist circumference, elevated triglycerides, reduced high-density lipoprotein cholesterol, elevated blood pressure, and elevated fasting glucose. The pathophysiologic basis of metabolic syndrome is complex and reflects several interrelated disturbances of glucose and lipid homeostasis. Metabolic syndrome is prevalent in the United States and developed nations, and patients with this disorder are at risk for type 2 diabetes mellitus and cardiovascular disease, underscoring the need for prompt patient identification and management. The first-line approach to control of metabolic syndrome is weight control and exercise. A wide range of pharmacologic interventions (eg, statins, antihypertensive drugs, insulin sensitizers, and thiazolidinediones) have been shown to be effective in controlling the individual components of metabolic syndrome. Obesity, which is a necessary component of metabolic syndrome, has reached epidemic proportions in the United States. Although lifestyle management or medications can control the underlying risk factors and most of the components of metabolic syndrome, long-term weight loss is difficult to achieve. Several promising pharmacologic interventions that may have an important role in the management of metabolic syndrome by treating adipose tissue-mediated metabolic disturbances are in the early stages of development.